Richard D. Kim

5.5k total citations · 2 hit papers
198 papers, 3.6k citations indexed

About

Richard D. Kim is a scholar working on Oncology, Surgery and Pulmonary and Respiratory Medicine. According to data from OpenAlex, Richard D. Kim has authored 198 papers receiving a total of 3.6k indexed citations (citations by other indexed papers that have themselves been cited), including 130 papers in Oncology, 71 papers in Surgery and 55 papers in Pulmonary and Respiratory Medicine. Recurrent topics in Richard D. Kim's work include Colorectal Cancer Treatments and Studies (55 papers), Pancreatic and Hepatic Oncology Research (47 papers) and Cholangiocarcinoma and Gallbladder Cancer Studies (47 papers). Richard D. Kim is often cited by papers focused on Colorectal Cancer Treatments and Studies (55 papers), Pancreatic and Hepatic Oncology Research (47 papers) and Cholangiocarcinoma and Gallbladder Cancer Studies (47 papers). Richard D. Kim collaborates with scholars based in United States, Canada and France. Richard D. Kim's co-authors include Dae Won Kim, Amit Mahipal, Chetasi Talati, Paolo Abada, Michael A. Morse, Aiwu Ruth He, Weijing Sun, Richard S. Finn, Michael J. Schell and Federico Aucejo and has published in prestigious journals such as Journal of the American Chemical Society, Journal of Biological Chemistry and Journal of Clinical Oncology.

In The Last Decade

Richard D. Kim

185 papers receiving 3.6k citations

Hit Papers

align trajectories

What are hit papers?

Hit papers significantly outperform the citation benchmark for their cohort. A paper qualifies if it has ≥500 total citations, achieves ≥1.5× the top-1% citation threshold for papers in the same subfield and year (this is the minimum needed to enter the top 1%, not the average within it), or reaches the top citation threshold in at least one of its specific research topics.

The Role of Angiogenesis in Hepatocellular Carcinoma

2018 417 citations Richard D. Kim, Aiwu Ruth He et al. profile →
A Phase 2 Multi-institutional Study of Nivolumab for Patients With Advanced Refractory Biliary Tract Cancer

2020 306 citations Richard D. Kim, Vincent Chung et al. profile →

Peers

Countries citing papers authored by Richard D. Kim

Since Specialization

Citations

This map shows the geographic impact of Richard D. Kim's research. It shows the number of citations coming from papers published by authors working in each country. You can also color the map by specialization and compare the number of citations received by Richard D. Kim with the expected number of citations based on a country's size and research output (numbers larger than one mean the country cites Richard D. Kim more than expected).

Fields of papers citing papers by Richard D. Kim

Since Specialization

Physical SciencesHealth SciencesLife SciencesSocial Sciences

This network shows the impact of papers produced by Richard D. Kim. Nodes represent research fields, and links connect fields that are likely to share authors. Colored nodes show fields that tend to cite the papers produced by Richard D. Kim. The network helps show where Richard D. Kim may publish in the future.

Co-authorship network of co-authors of Richard D. Kim

This figure shows the co-authorship network connecting the top 25 collaborators of Richard D. Kim. A scholar is included among the top collaborators of Richard D. Kim based on the total number of citations received by their joint publications. Widths of edges represent the number of papers authors have co-authored together. Node borders signify the number of papers an author published with Richard D. Kim. Richard D. Kim is excluded from the visualization to improve readability, since they are connected to all nodes in the network.

All Works

Sort: Min cites: Since: Top N: Style:

20 of 20 papers shown

#	Work	Indexed citations
1	Real-World Study of Patients with Metastatic Colorectal Cancer and Long-Term Response to Regorafenib in the USA 2025 ·Cancers ·Richard D. Kim, Xiaoyun Pan, (unknown), Orsolya Lunacsek, Federica Pisa, (unknown), Marc Peeters	0
2	Detecting Early Recurrence With Circulating Tumor DNA in Stage I-III Biliary Tract Cancer After Curative Resection 2025 ·JCO Precision Oncology ·(unknown), Aiwu Ruth He, (unknown), (unknown), Daniel A. Anaya, Jason W. Denbo, Catherine Bridges, Antony Tin, Vasily N. Aushev, Charuta C. Palsuledesai, (unknown), Adham Jurdi, Minetta C. Liu, Richard D. Kim	5
3	Real-World Experiences Using Atezolizumab + Bevacizumab for the Treatment of Unresectable Hepatocellular Carcinoma: A Multicenter Study 2025 ·Cancers ·Maen Abdelrahim, Abdullah Esmail, Richard D. Kim, Sukeshi Patel Arora, (unknown), (unknown), (unknown), (unknown), (unknown), Fan Mu, (unknown), Sairy Hernandez, Nguyen H. Tran	0
4	Real-world use of pemigatinib for the treatment of cholangiocarcinoma in the US 2024 ·The Oncologist ·Kim Saverno, Kristin M. Zimmerman Savill, (unknown), (unknown), Michael Rodriguez, Bruce A. Feinberg, Haobo Ren, (unknown), Richard D. Kim	0
5	A phase 2a study of NT-I7 (efineptakin alfa), a long-acting IL-7, and pembrolizumab to evaluate efficacy, including overall survival, in hard-to-treat gastrointestinal tumors. 2024 ·Journal of Clinical Oncology ·Richard D. Kim, Hirva Mamdani, Minal Barve, Melissa L. Johnson, Julie A. Murphy, (unknown), Sara Ferrando‐Martínez, Byung Ha Lee, Se Hwan Yang, Marya Chaney, Aung Naing	1
6	Real-World Effectiveness of First Line Lenvatinib Therapy in Advanced Hepatocellular Carcinoma: Current Insights 2024 ·PubMed ·Tiago Biachi De Castria, Richard D. Kim	0
7	Pembrolizumab Plus mFOLFOX7 or FOLFIRI for Microsatellite Stable/Mismatch Repair-Proficient Metastatic Colorectal Cancer: KEYNOTE-651 Cohorts B and D 2024 ·Clinical Colorectal Cancer ·Richard D. Kim, Mustapha Tehfé, Petr Kavan, Jorge Chaves, Jeremy Kortmansky, Eric X. Chen, Christopher H. Lieu, Lucas Wong, Marwan Fakih, Kristen Spencer, Qing Zhao, (unknown), (unknown), Pierre Leconte, David E. Adelberg, E. Gabriela Chiorean	8
8	Biomarker Analysis from a Phase I/Ib Study of Regorafenib and Nivolumab in Mismatch Repair-Proficient Advanced Refractory Colorectal Cancer 2024 ·Cancers ·Dae Won Kim, Youngchul Kim, Bence Kővári, María Carmen Riesco Martínez, (unknown), (unknown), Rutika Mehta, Jonathan Strosberg, Iman Imanirad, Richard D. Kim	2
9	Association between posttreatment α‐fetoprotein reduction and outcomes in real‐world US patients with advanced hepatocellular carcinoma 2023 ·Cancer ·Ghassan K. Abou‐Alfa, Xiaoliang Wang, Christina M. Parrinello, Anala Gossai, Richard D. Kim, (unknown), Rebecca A. Miksad	5
10	A phase I, first-in-human study of TAK-164, an antibody–drug conjugate, in patients with advanced gastrointestinal cancers expressing guanylyl cyclase C 2023 ·Cancer Chemotherapy and Pharmacology ·Richard D. Kim, Alexis D. Leal, Aparna R. Parikh, David P. Ryan, Shining Wang, Brittany Bahamón, Neeraj Gupta, Aaron J. Moss, (unknown), Harry Miao, Haig Inguilizian, James M. Cleary	12
11	Radioembolization with Yttrium-90 Glass Microspheres as a First-Line Treatment for Unresectable Intrahepatic Cholangiocarcinoma—A Prospective Feasibility Study 2023 ·Journal of Vascular and Interventional Radiology ·Béla Kis, Ravi Shridhar, Rahul Mhaskar, (unknown), Jessica M. Frakes, Ghassan El‐Haddad, Junsung Choi, Richard D. Kim, Sarah E. Hoffe	7
12	Unresectable Intrahepatic Cholangiocarcinoma Treated with Radiation Segmentectomy/Lobectomy Using Yttrium 90-labeled Glass Microspheres 2022 ·Journal of Clinical and Experimental Hepatology ·(unknown), Rahul Mhaskar, Richard D. Kim, Daniel Anaya, Jessica M. Frakes, Sarah E. Hoffe, Junsung Choi, Béla Kis	8
13	BRAF Mutations Are Associated with Poor Survival Outcomes in Advanced-stage Mismatch Repair-deficient/Microsatellite High Colorectal Cancer 2022 ·The Oncologist ·Elaine Tan, Junmin Whiting, Hao Xie, Iman Imanirad, Estrella M. Carballido, Seth Felder, Jessica M. Frakes, (unknown), Christine M. Walko, Jennifer B. Permuth, (unknown), Richard D. Kim, Daniel A. Anaya, Jason B. Fleming, İbrahim Halil Şahin	18
14	Biomarker analysis from a phase II multi-institutional study of nivolumab in patients with advanced refractory biliary tract cancer 2022 ·European Journal of Cancer ·Dae Won Kim, Youngchul Kim, Bence Kővári, Vincent Chung, Olatunji B. Alese, Bassel F. El‐Rayes, Daneng Li, Wungki Park, Richard D. Kim	7
15	A phase I/Ib study of regorafenib and nivolumab in mismatch repair proficient advanced refractory colorectal cancer 2022 ·European Journal of Cancer ·Richard D. Kim, Bence Kővári, María Carmen Riesco Martínez, Hao Xie, İbrahim Halil Şahin, Rutika Mehta, Jonathan Strosberg, Iman Imanirad, Masoumeh Ghayouri, Youngchul Kim, Dae Won Kim	53
16	Human Epidermal Growth Factor Receptor 2–Targeting Approaches for Colorectal Cancer: Clinical Implications of Novel Treatments and Future Therapeutic Avenues 2022 ·JCO Oncology Practice ·(unknown), Elaine Tan, (unknown), Todd C. Knepper, Christine M. Walko, Seth Felder, Richard D. Kim, İbrahim Halil Şahin	11
17	The Application of Circulating Tumor DNA in the Screening, Surveillance, and Treatment Monitoring of Colorectal Cancer 2020 ·Annals of Surgical Oncology ·Hao Xie, Richard D. Kim	5
18	A multi‐institutional phase 2 trial of regorafenib in refractory advanced biliary tract cancer 2020 ·Cancer ·Richard D. Kim, Hanna K. Sanoff, Andrew Poklepovic, Heloisa P. Soares, Jongphil Kim, Jing Lyu, Yingmiao Liu, Andrew B. Nixon, Dae Won Kim	34
19	Phase 2 study of copanlisib in combination with gemcitabine and cisplatin in advanced biliary tract cancers 2020 ·Cancer ·Elaine Tan, Biwei Cao, Jongphil Kim, Taymeyah Al‐Toubah, Rutika Mehta, Barbara A. Centeno, Richard D. Kim	23
20	Intrahepatic Cholangiocarcinoma Treated with Transarterial Yttrium-90 Glass Microsphere Radioembolization: Results of a Single Institution Retrospective Study 2018 ·Journal of Vascular and Interventional Radiology ·Alexandra Gangi, (unknown), (unknown), (unknown), Jennifer Sweeney, Junsung Choi, Ghassan El‐Haddad, (unknown), Nainesh Parikh, Bülent Arslan, Sarah E. Hoffe, Jessica M. Frakes, Gregory M. Springett, Daniel A. Anaya, Mokenge P. Malafa, Dung‐Tsa Chen, Yunyun Chen, Richard D. Kim, Ravi Shridhar, Béla Kis	56

Rankless uses publication and citation data sourced from OpenAlex, an open and comprehensive bibliographic database. While OpenAlex provides broad and valuable coverage of the global research landscape, it—like all bibliographic datasets—has inherent limitations. These include incomplete records, variations in author disambiguation, differences in journal indexing, and delays in data updates. As a result, some metrics and network relationships displayed in Rankless may not fully capture the entirety of a scholar's output or impact.

Explore authors with similar magnitude of impact